Targeted Oncology1d
SELECT Trial Outcomes Support Lenvatinib as RAI-Refractory DTC Therapy
During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...
Eisai: Still Relatively Modest Market-Implied Expectations For Leqembi
Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...
Cure Today3d
FDA Approves MI Cancer Seek as Companion Diagnostic for Adult and Pediatric Patients With Cancer
MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...
Newly Funded Medicine To Benefit 110 More People With Thyroid, Liver, And Kidney Cancer
Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...
Pharmac green lights free treatment for some thyroid, liver cancer patients
People with some types of thyroid and liver cancer are getting free access to a targeted treatment for the first time, with ...
Knight Therapeutics Reports Third Quarter 2024
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial ...